Inspyr Therapeutics Short Interest Ratio and Short Volume

Short interest is the volume of Inspyr Therapeutics shares that have been sold short but have not yet been covered or closed out. As of January 29th, traders have sold 158,400 shares of NSPX short.

Inspyr Therapeutics saw a increase in short interest during the month of January. As of January 29th, there was short interest totaling 158,400 shares, an increase of 161.0% from the previous total of 60,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.00% of Inspyr Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Inspyr Therapeutics: Acura Pharmaceuticals, Inc. (0.00%), International Stem Cell Co. (0.00%), Intellipharmaceutics International Inc. (0.00%), Kaya Holdings, Inc. (0.00%), American Bio Medica Co. (0.00%), Cotinga Pharmaceuticals Inc. (0.00%), Amarantus BioScience Holdings, Inc. (0.00%), BriaCell Therapeutics Corp. (0.00%), Boston Therapeutics, Inc. (0.00%), and Immune Pharmaceuticals, Inc. (0.00%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Aon Plc ($5.34 billion), Charter Communications, Inc. ($5.03 billion), ViacomCBS Inc. ($4.99 billion), DuPont de Nemours, Inc. ($4.72 billion), Analog Devices, Inc. ($4.57 billion), Snap Inc. ($3.87 billion), Moderna, Inc. ($3.58 billion), Futu Holdings Limited ($2.75 billion), Snowflake Inc. ($2.43 billion), and Palantir Technologies Inc. ($2.18 billion). View all of the most shorted stocks.

Short selling NSPX is an investing strategy that aims to generate trading profit from Inspyr Therapeutics as its price is falling. To short Inspyr Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Inspyr Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Inspyr Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NSPX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NSPX, twice per month. The most recent reporting period available is January, 29 2021.